Pregnancy Pregnancy Complications

Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives

Liu H, Huang W, Hu Z, Han J, Gao R, Qin L

Frontiers in immunology, 17, 1815957, 2026
DOI 10.3389/fimmu.2026.1815957 PMID 42064042 PMC PMC13126737

RRM Academy Synopsis

Low regulatory T cells are linked to recurrent miscarriage

A 2026 narrative review of human and animal studies reports that women with recurrent miscarriage or preeclampsia often have fewer or weaker regulatory T cells. These immune cells help a mother's body tolerate her baby. The review also surveys treatments aimed at these cells, including emerging ones whose use in pregnancy is in its infancy.

Key Findings

  • Women with recurrent implantation failure, recurrent miscarriage, preeclampsia, or preterm birth often have fewer or less active regulatory T cells, in blood and pregnancy lining, than women with healthy pregnancies.
  • In healthy pregnancy, regulatory T cells in the blood typically rise early, peak around mid-pregnancy, and fall before labor.
  • Progesterone and human chorionic gonadotropin support regulatory T cell expansion and recruitment. Direct evidence for this hormonal effect at the maternal-fetal interface comes largely from mouse models.
  • Low numbers of circulating regulatory T cells in early pregnancy mark a higher chance of later loss in high-risk women.
  • The review discusses treatments aimed at these cells, including intravenous immunoglobulin, glucocorticoids, paternal lymphocyte immunotherapy, metformin, and engineered cells. The authors call chimeric antigen receptor Tregs still theoretical in pregnancy.

Interpretation

The paper is a narrative review of human studies, animal experiments, and laboratory work, drawn from searches of three databases covering 1995 to 2025. The review summarizes published work. The human evidence describes group differences in immune cell counts and function. The authors state that much of the mechanistic insight comes from animal models or blood analyses, with limited direct study of human placental tissue.

RRM Context

The review describes progesterone as a hormone that helps regulatory T cells grow in number. In early pregnancy, progesterone comes from the corpus luteum, the structure that forms after ovulation, so the review's progesterone point depends on ovulation having occurred. Restorative reproductive medicine looks for the cause first. It sees unexplained recurrent miscarriage as undiagnosed. The authors name this condition as a research priority for immune treatments.

Abstract

Regulatory T cells (Tregs) play a central role in maintaining immune tolerance and supporting maternal-fetal homeostasis throughout human pregnancy. Clinical and experimental evidence demonstrates that dysregulation of peripheral and decidual Tregs manifested as quantitative deficits, impaired suppressive function or lineage instability increased the risk of various pathological pregnancies, such as recurrent implantation failure (RIF), recurrent spontaneous abortion (RSA), pre-eclampsia (PE) and preterm birth (PTB). Recently, novel therapeutic strategies targeting Tregs have emerged in oncology, transplantation, and autoimmune diseases. However, their application in pathological pregnancy remains in its infancy. This review outlines the spatiotemporal dynamics of peripheral and decidual Tregs throughout gestation, elucidating their roles in maintaining maternal-fetal homeostasis and their dysregulation in pathological pregnancies. We also critically evaluated the therapeutic strategies targeting Tregs and Tregs-associated signaling pathways, including hormonal support, traditional intravenous immunoglobulin, as well as emerging interventions such as immunometabolic reprogramming and engineered cellular therapies like chimeric antigen receptor Tregs. This review may provide insights for understanding the roles of Tregs in physiological and pathological pregnancy, as well as provide new idea in the immunotherapy of pathological pregnancy.

Topics

By this author

Related research

Pregnancy › Pregnancy Complications › Hypertensive Disorders · Genetics and Immunology › Reproductive Immunology › Implantation Immunology
Huimin Liu, Wanrong Huang, Zhengyan Hu, Jinbiao Han, Rui Gao, Lang Qin
H Liu, W Huang, Z Hu, J Han, R Gao, L Qin
PMID 42064042 42064042 DOI 10.3389/fimmu.2026.1815957 10.3389/fimmu.2026.1815957 Liu et al. 2026, Liu 2026